Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 226: Line 226:
 
|-
 
|-
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Stem cell mobilization]]
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Stem cell mobilization]]
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Allogeneic HSCT conditioning regimens]]
+
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Allogeneic HSCT]]
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]]
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Autologous HSCT conditioning regimens]]
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]
 
|style="width: 25%; border-left:solid 10px #756bb1; background-color:#efedf5"|[[Graft versus host disease (GVHD)]]

Revision as of 13:23, 14 October 2017

HemOnc.org - A Free Hematology/Oncology Reference

Regimens: 4,428 Regimen variants: 6,546
Solid Tumors Malignant Hematology Transplant Classical Hematology
Mobile Version Editorial Board Desktop Version
Disease index Drug index Regimen index General reference
If this is your first time visiting, please go to the tutorial page or just start exploring!

Links to Main Disease Pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, HER-2 positive
Dermatologic Oncology
Melanoma Skin, basal & squamous cancer Merkel cell carcinoma Cutaneous T-cell lymphoma (CTCL)
Endocrine Oncology
Germ cell tumors Neuroendocrine tumors Thyroid cancer
Gastrointestinal Oncology
Anal cancer Colon cancer Esophageal cancer Gastric cancer
Gastrointestinal stromal tumor (GIST) Hepatobiliary cancer Pancreatic cancer Rectal cancer
Genitourinary Oncology
Bladder cancer Germ cell tumors Penile cancer Prostate cancer
Renal cancer (RCC) Testicular cancer
Gynecologic Oncology
Cervical cancer Germ cell tumors Ovarian cancer Uterine cancer
Head & Neck Oncology
Head and neck cancer Thyroid cancer
Neuro-Oncology
Central nervous system (CNS) cancer Glioblastoma CNS leukemia CNS lymphoma
Pediatric Oncology
Neuroblastoma
Sarcoma
Bone cancer Ewing's sarcoma Gastrointestinal stromal tumor (GIST) Osteosarcoma
Sarcoma
Thoracic Oncology
Esophageal cancer Lung cancer, non-small cell (NSCLC) Lung cancer, small cell (SCLC) Mesothelioma
Thymoma
Site-agnostic
MSI-H or dMMR Unknown primary

back to top
Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) B-cell acute lymphoblastic leukemia (B-ALL) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myelogenous leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma CNS lymphoma Diffuse large B-cell lymphoma (DLBCL) HIV-associated lymphoma
Hodgkin lymphoma (HL) Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL) Primary mediastinal B-cell lymphoma (PMBL)
Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (MM) Plasma cell leukemia
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK/T-cell lymphoma, nasal type
Large granular lymphocytic (LGL) leukemia NK/T-cell lymphoma Peripheral T-cell Lymphoma (PTCL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocyte disorders
Erdheim-Chester disease Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis

back to top
Transplant
Stem cell mobilization Allogeneic HSCT Autologous HSCT conditioning regimens Graft versus host disease (GVHD)

back to top
Classical Hematology
Aplastic anemia Atypical hemolytic-uremic syndrome (aHUS) Autoimmune cytopenias Autoimmune thrombocytopenic purpura (ITP)
Coagulopathies Cold agglutinin disease Paroxysmal nocturnal hemoglobinuria (PNH) Sickle cell anemia
Thrombotic thrombocytopenic purpura (TTP) Venous thromboembolism (VTE)
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes continuous peer review.


Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details. Priorities of this project include:

  1. Creating a database of chemotherapy agents and other medications.
  2. Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
  3. Sample order sets and examples of supportive medications used with treatment regimens
  4. Aggregating useful links to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.

Additional possibilities for this project may include:

  1. Creating summaries of pivotal clinical trials
  2. Establishing homepages for ongoing clinical trials that contain information and sites of participation
  3. Checklists for common clinical scenarios/diseases
  4. Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.